Kymera Therapeutics (KYMR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Protein Degradationsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 5.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 18.0% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
- Kymera Therapeutics to Participate in Upcoming September Investor Conferences
- Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
- Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
- Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)
- Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
- Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
- Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Kymera Therapeutics.
Full KYMR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.